Swisscom profit drops 23% as Vodafone Italia costs weigh on results
Investing.com - Bernstein SocGen Group has reiterated an Outperform rating and $135.00 price target on Gilead Sciences (NASDAQ:GILD) following the company’s third-quarter earnings report.
Gilead reported Q3 revenue of $7.77 billion, representing a 4% increase and exceeding consensus estimates of $7.47 billion, along with earnings per share of $2.47, up 16.3% compared to expectations of $2.12.
The quarter included a $400 million non-recurring revenue item that boosted EPS by 25 cents, though even without this payment, EPS would have exceeded expectations primarily due to operating expense management, while revenue would have slightly missed forecasts by less than 1% due to weakness in Veklury, CAR-T pressures, and underperformance of Trodelvy.
Gilead has raised its full-year guidance, with revenue now projected at $28.4-28.7 billion (previously $28.3-28.7 billion), representing a 0.2% increase at the midpoint, and EPS guidance of $8.05-8.25 (previously $7.95-8.25), a 0.6% increase at the midpoint.
Bernstein’s analyst highlighted that Gilead’s "HIV core is firing & Yeztugo looking solid," despite noting "some challenges in oncology," maintaining a positive outlook on the company’s prospects.
In other recent news, Gilead Sciences Inc . reported its third-quarter earnings for 2025, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $2.47, exceeding the forecasted $2.15, resulting in a 14.88% surprise. Revenue for the quarter reached $7.8 billion, which also surpassed the anticipated $7.45 billion. Despite the positive earnings report, the stock experienced only a modest movement. Analysts have noted the company’s performance, though specific upgrades or downgrades were not mentioned in the recent news. The earnings and revenue results are significant for investors, reflecting Gilead Sciences’ strong financial performance. These developments are part of the latest updates concerning the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.